NO943625L - Monoklonale antistoffer mot interferonreseptoren med nöytraliserende aktivitet mot type-I-interferon - Google Patents

Monoklonale antistoffer mot interferonreseptoren med nöytraliserende aktivitet mot type-I-interferon

Info

Publication number
NO943625L
NO943625L NO943625A NO943625A NO943625L NO 943625 L NO943625 L NO 943625L NO 943625 A NO943625 A NO 943625A NO 943625 A NO943625 A NO 943625A NO 943625 L NO943625 L NO 943625L
Authority
NO
Norway
Prior art keywords
interferon
monoclonal antibodies
neutralizing activity
receptor
type
Prior art date
Application number
NO943625A
Other languages
English (en)
Norwegian (no)
Other versions
NO943625D0 (no
Inventor
Patrick Benoit
Francois Meyer
Debborah Maguire
Ivan Plavec
Michael G Tovey
Original Assignee
Europ De Biotechnologie Sa Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Europ De Biotechnologie Sa Lab filed Critical Europ De Biotechnologie Sa Lab
Publication of NO943625D0 publication Critical patent/NO943625D0/no
Publication of NO943625L publication Critical patent/NO943625L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO943625A 1992-03-31 1994-09-29 Monoklonale antistoffer mot interferonreseptoren med nöytraliserende aktivitet mot type-I-interferon NO943625L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92400902A EP0563487A1 (fr) 1992-03-31 1992-03-31 Anticorps monoclonaux contre le récepteur d'interféron avec une activité contre l'interféron du type I
PCT/EP1993/000770 WO1993020187A1 (fr) 1992-03-31 1993-03-30 Anticorps monoclonaux dresses contre le recepteur d'interferon et dotes d'une activite neutralisante dirigee contre l'interferon de type i

Publications (2)

Publication Number Publication Date
NO943625D0 NO943625D0 (no) 1994-09-29
NO943625L true NO943625L (no) 1994-11-11

Family

ID=8211644

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943625A NO943625L (no) 1992-03-31 1994-09-29 Monoklonale antistoffer mot interferonreseptoren med nöytraliserende aktivitet mot type-I-interferon

Country Status (18)

Country Link
US (5) US5919453A (fr)
EP (3) EP0563487A1 (fr)
JP (2) JP3836500B2 (fr)
AT (2) ATE368055T1 (fr)
AU (2) AU679909B2 (fr)
BG (1) BG99141A (fr)
CA (1) CA2133106C (fr)
CZ (1) CZ236994A3 (fr)
DE (2) DE69332997T2 (fr)
DK (2) DK0633931T3 (fr)
ES (2) ES2199941T3 (fr)
FI (1) FI944509A (fr)
HU (1) HUT69995A (fr)
NO (1) NO943625L (fr)
NZ (1) NZ251343A (fr)
PT (2) PT633931E (fr)
RU (1) RU94045826A (fr)
WO (1) WO1993020187A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (fr) 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Anticorps monoclonaux contre le récepteur d'interféron avec une activité contre l'interféron du type I
CA2171955A1 (fr) * 1993-09-17 1995-03-23 Michael G. Tovey Composition pharmaceutique renfermant des anticorps monoclonaux anti-recepteur de l'interferon, avec action neutralisante contre l'interferon de type i
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
CN1068524C (zh) * 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
US6376067B1 (en) * 1998-12-21 2002-04-23 Mitsubishi Polyester Film, Llc Silicone coated film with back side slip control coating and method of controlling slip of such film
GB0001712D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
WO2002067760A2 (fr) * 2001-01-09 2002-09-06 Baylor Research Institute Traitements de maladies auto-immunes chez un sujet et techniques diagnostiques in vitro
AU2007202840B2 (en) * 2001-01-09 2011-07-28 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
AU2007203559B2 (en) * 2003-04-23 2010-09-02 E. R. Squibb & Sons, L.L.C. Compositions and methods for the therapy of inflammatory bowel disease
CA2823468A1 (fr) * 2003-04-23 2004-11-04 Medarex, L.L.C. Compositions et techniques destinees a la therapie d'une maladie intestinale inflammatoire
US7619070B2 (en) * 2003-04-23 2009-11-17 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
PT1711207E (pt) 2003-12-10 2013-02-13 Medarex Inc Anticorpos alfa interferão e seus usos
WO2005118647A2 (fr) * 2004-05-18 2005-12-15 Genentech, Inc. Principaux variants de proteines de coque pour affichage c-terminal et bi-terminal
PL1781705T3 (pl) * 2004-06-21 2015-03-31 Squibb & Sons Llc Antyciała receptora interferonów alfa I oraz ich zastosowania
EP1796722A1 (fr) * 2004-10-07 2007-06-20 Universität Zürich Agents bloquants de l'interferon de type 1 dans la prevention et le traitement du psoriasis
KR101363120B1 (ko) 2005-02-10 2014-02-13 베일러 리서치 인스티튜트 항-인터페론 알파 모노클로날 항체 및 사용 방법
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
CA2612378A1 (fr) * 2005-06-22 2007-01-04 Genentech, Inc. Methodes et compositions permettant de cibler ifnar2
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
US8685400B2 (en) 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
CA2713981C (fr) 2008-02-08 2016-11-01 Medimmune, Llc Anticorps anti-ifnar1 ayant une affinite reduite pour le ligand fc
CN102083859B (zh) 2008-05-07 2014-09-17 阿哥斯医疗公司 人源化抗人干扰素-α抗体
WO2011109338A1 (fr) * 2010-03-01 2011-09-09 Alexion Pharmaceuticals Inc. Méthodes et compositions pour le traitement de la maladie de degos
WO2013134146A1 (fr) * 2012-03-07 2013-09-12 The Regents Of The University Of California Procédés et compositions pour le traitement d'infections virales par blocage de l'activité de l'interféron de type i
HRP20240603T1 (hr) 2016-07-01 2024-07-19 Resolve Therapeutics, Llc Optimizirane fuzije binukleaze i postupci njihove upotrebe
CN107074943B (zh) 2016-07-14 2018-08-24 中国科学院生物物理研究所 I型干扰素受体抗体及其用途
CN111315767A (zh) 2017-08-22 2020-06-19 萨纳生物有限责任公司 可溶性干扰素受体及其用途
CN115925950A (zh) * 2019-01-31 2023-04-07 广东旋玉健康生物科技有限公司 新型抗ifnar1抗体
EP4393937A1 (fr) 2021-08-26 2024-07-03 Duality Biologics (Suzhou) Co., Ltd. Composé stéroïde et conjugué de celui-ci
CN115028730B (zh) * 2022-05-17 2022-11-08 诺赛联合(北京)生物医学科技有限公司 一种成体干细胞衍生的类器官制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953132A (en) 1955-10-27 1960-09-20 Baxter Laboratories Inc Parenteral solution equipment
US3066671A (en) 1959-10-27 1962-12-04 Milton J Cohen Disposable additive container
US3608550A (en) 1969-05-07 1971-09-28 Becton Dickinson Co Transfer needle assembly
BE791340A (fr) 1972-01-06 1973-03-01 Becton Dickinson Co Nouveaux procede et appareil de prelevement de culture et d'identification de micro-organismes des humeurs
US4024857A (en) 1974-12-23 1977-05-24 Becton, Dickinson And Company Micro blood collection device
US4300404A (en) 1977-12-01 1981-11-17 Becton, Dickinson And Company Liquid specimen container
US4116066A (en) 1977-12-12 1978-09-26 Becton, Dickinson And Company Specimen sampler cup
US5516515A (en) * 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
IL88377A (en) * 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon
US5889151A (en) * 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
FR2653445B1 (fr) * 1989-10-20 1994-07-29 Centre Nat Rech Scient Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
FR2657881A1 (fr) * 1990-02-05 1991-08-09 Europ Biotechnologie Lab Nouveaux polypeptides hydrosolubles, sequences d'adn, nouvelles cellules, procede de preparation, applications et compositions renfermant lesdits polypeptides.
IL99232A0 (en) * 1990-08-20 1992-07-15 Univ Columbia Methods for producing rna viruses from cdna
ATE181961T1 (de) * 1991-04-17 1999-07-15 Medisup Int Nv Neue wasserlösliche polypeptide mit hoher affinität für alpha- und beta- interferone
EP0563487A1 (fr) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Anticorps monoclonaux contre le récepteur d'interféron avec une activité contre l'interféron du type I
DE69332485T2 (de) * 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
US6558661B1 (en) * 1992-12-29 2003-05-06 Genentech, Inc. Treatment of inflammatory bowel disease with IFN-γ inhibitors
AU1854695A (en) * 1994-03-07 1995-09-25 Imperial College Of Science, Technology And Medicine The use of interferon subtypes in the preparation of medicaments to treat viral infections
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor

Also Published As

Publication number Publication date
EP1329459A2 (fr) 2003-07-23
PT1329459E (pt) 2007-11-07
EP0633931B1 (fr) 2003-05-21
RU94045826A (ru) 1996-11-10
DE69332997T2 (de) 2004-05-19
AU2349697A (en) 1997-07-24
BG99141A (bg) 1995-07-28
DE69332997D1 (de) 2003-06-26
DE69334158T2 (de) 2008-04-10
US20070128701A1 (en) 2007-06-07
ATE241008T1 (de) 2003-06-15
DK0633931T3 (da) 2003-09-15
CA2133106C (fr) 2009-06-30
EP1329459B1 (fr) 2007-07-25
EP0633931A1 (fr) 1995-01-18
NO943625D0 (no) 1994-09-29
CA2133106A1 (fr) 1993-10-14
FI944509A (fi) 1994-11-29
US5919453A (en) 1999-07-06
US20020055492A1 (en) 2002-05-09
US20080226647A1 (en) 2008-09-18
DE69334158D1 (de) 2007-09-06
WO1993020187A1 (fr) 1993-10-14
US7179465B2 (en) 2007-02-20
NZ251343A (en) 1997-07-27
ES2290241T3 (es) 2008-02-16
US20040191840A1 (en) 2004-09-30
US7465451B2 (en) 2008-12-16
ATE368055T1 (de) 2007-08-15
AU679909B2 (en) 1997-07-17
HU9402823D0 (en) 1995-01-30
EP1329459A3 (fr) 2003-09-10
FI944509A0 (fi) 1994-09-29
HUT69995A (en) 1995-09-28
JPH07505526A (ja) 1995-06-22
AU706473B2 (en) 1999-06-17
CZ236994A3 (en) 1995-02-15
DK1329459T3 (da) 2007-11-26
EP0563487A1 (fr) 1993-10-06
JP3836500B2 (ja) 2006-10-25
ES2199941T3 (es) 2004-03-01
JP2006089494A (ja) 2006-04-06
AU3890793A (en) 1993-11-08
PT633931E (pt) 2003-09-30
US6787634B2 (en) 2004-09-07

Similar Documents

Publication Publication Date Title
NO943625L (no) Monoklonale antistoffer mot interferonreseptoren med nöytraliserende aktivitet mot type-I-interferon
ATE412430T1 (de) Monoklonale antikörper die ligandbindung an den cd22-rezeptor in reifen b-zellen unterbinden.
ATE255902T1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten
ES2111524T3 (es) Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos.
TR199901710T2 (xx) IL-8 resept�r antagonistleri.
NO982062D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
ATE305971T1 (de) Monoklonale antikörper und fv gegen das cd2 antigen
DK0461177T3 (da) Humant intra-acrosomalt spermantigen til anvendelse i en svangerskabsforebyggende vaccine
DE69633973D1 (de) Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
NO20004946L (no) Humanisert antistoff mot human vevsfaktor (TF) og fremgangsmåte ved fremstilling av det humaniserte antistoff
DE69435126D1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
DE69330643D1 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
DK1449850T3 (da) Humane CDR-graftede antistoffer eller antistoffragmenter deraf
ATE386805T1 (de) Verwendungen eines borreliaziden epitops des aussermembranproteins c von borrelia burgdorferi (ospc) als impstoff
ES2109242T3 (es) Anticuerpos monoclonales contra inmunoglobulina e humana.
DK165982C (da) Imidazolylguanidinderivater og laegemidler, der indeholder disse forbindelser
TR199901761T2 (xx) IL-8 resept�r antagonistleri.
ATE364627T1 (de) G-protein gekoppelter rezeptor mit vergrösserter, extrazellulärer domäne
NO943653D0 (no) Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon
CA2308007A1 (fr) Potentialisateur pour anticorps anti-tumeur lymphoide
TR27329A (tr) Yeni metazoan parazit antigenler, bunlari kodlayan nükleik asidler.
DE69333416D1 (de) Immunologisches Verfahren für die Detektion von Pferde-Herpesvirus Typ 1 und 4 glycoprotein G Antikörper
ATE205255T1 (de) Spezifische antikörper gegen aktivierte plättchen,ihre herstellung und ihre verwendung in diagnose und therapie
CA2151945A1 (fr) Epreuve et traitement pour maladies demyelinisantes, comme la sclerose en plaques